论文部分内容阅读
目的探索孟鲁司特与鼻用丙酸氟替卡松联合用于治疗中-重度持续性变应性鼻炎(AR)的效果。方法 55例中-重度持续性AR患者,根据治疗方法的不同分为观察组(27例)和对照组(28例)。对照组患者单用丙酸氟替卡松鼻喷剂治疗,观察组患者在对照组的基础上加用孟鲁司特治疗,对比分析两组患者的治疗效果。结果观察组患者的治疗总有效率为96.30%,明显高于对照组的78.57%(P<0.05)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。治疗4周后,观察组的免疫球蛋白E(Ig E)水平明显低于对照组(P<0.05)。结论对中-重度持续性AR采用孟鲁司特联合鼻用丙酸氟替卡松治疗效果确切,有助于促进患者临床症状的缓解,提高生活质量。
Objective To explore the effect of combination of montelukast and nasal fluticasone propionate for the treatment of moderate-severe persistent allergic rhinitis (AR). Methods 55 patients with moderate-severe persistent AR were divided into observation group (27 cases) and control group (28 cases) according to the different treatment methods. Patients in the control group were treated with fluticasone propionate nasal spray only. Patients in the observation group were treated with montelukast on the basis of the control group, and the therapeutic effect was compared between the two groups. Results The total effective rate of observation group was 96.30%, which was significantly higher than that of control group (78.57%, P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). After 4 weeks of treatment, the level of IgE in the observation group was significantly lower than that in the control group (P <0.05). Conclusion The treatment of moderate-severe AR with montelukast combined with nasal fluticasone propionate is effective in promoting the relief of clinical symptoms and improving the quality of life.